Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications
Carolina Boni, Valeria Barili, Greta Acerbi, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 11, pp. 2754-2754
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Grace Lai‐Hung Wong, Ed Gane, Anna S. Lok
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1249-1262
Open Access | Times Cited: 143
Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches
Paola Fisicaro, Valeria Barili, Marzia Rossi, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 110
Development of therapeutic vaccines for the treatment of diseases
Yaomei Tian, Die Hu, Yuhua Li, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 44
Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases
Camille Rolin, Jacques Zimmer, Carole Seguin‐Devaux
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 7, pp. 643-661
Open Access | Times Cited: 11
Immunotherapy for advanced hepatocellular carcinoma, where are we?
Zhang Li, Jia Ding, Huiyan Li, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1874, Iss. 2, pp. 188441-188441
Open Access | Times Cited: 67
TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection
Kathrin Heim, Benedikt Binder, Sagar Sagar, et al.
Gut (2020) Vol. 70, Iss. 8, pp. 1550-1560
Open Access | Times Cited: 57
Innate and adaptive immune escape mechanisms of hepatitis B virus
Huajun Zhao, Yifei Hu, Qiuju Han, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 9, pp. 881-896
Open Access | Times Cited: 28
What will it take to cure hepatitis B?
Wen‐Juei Jeng, Anna S. Lok
Hepatology Communications (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 20
HBV Vaccines: Advances and Development
Faisal Mahmood, Ruixian Xu, Maher Un Nisa Awan, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1862-1862
Open Access | Times Cited: 20
HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis
Riccardo Nevola, Domenico Beccia, Valerio Rosato, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7651-7651
Open Access | Times Cited: 17
Harnessing CD8+ T cell dynamics in hepatitis B virus‐associated liver diseases: Insights, therapies and future directions
Bing Yue, Yuxia Gao, Yi Hu, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 7
Open Access | Times Cited: 7
Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy
Ruimin Hong, Houli Zhao, Yiyun Wang, et al.
Bone Marrow Transplantation (2020) Vol. 56, Iss. 3, pp. 570-580
Open Access | Times Cited: 30
CAR-T Cell Therapy
Aamir Ahmad
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4303-4303
Open Access | Times Cited: 29
mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model
Dorien De Pooter, Wim Pierson, Soheil Pourshahian, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 237-237
Open Access | Times Cited: 3
Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Aguilar, et al.
Pathogens (2021) Vol. 10, Iss. 11, pp. 1440-1440
Open Access | Times Cited: 21
Model to predict on‐treatment restoration of functional HBV‐specific CD8+ cell response foresees off‐treatment HBV control in eAg‐negative chronic hepatitis B
Julia Peña‐Asensio, Henar Calvo Sánchez, Joaquín Míquel, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 55, Iss. 12, pp. 1545-1559
Open Access | Times Cited: 15
Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases
Ejuan Zhang, Zhiyong Ma, Mengji Lu
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 11
Open Access | Times Cited: 15
A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments
Béatrice Laupèze, Ventzislav Vassilev, Selim Badur
Expert Review of Gastroenterology & Hepatology (2023) Vol. 17, Iss. 11, pp. 1135-1147
Open Access | Times Cited: 8
Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10271-10271
Open Access | Times Cited: 20
Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs
Andrea Montisci, Maria Teresa Vietri, Vittorio Palmieri, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4797-4797
Open Access | Times Cited: 19
The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Aguilar, et al.
Vaccines (2021) Vol. 10, Iss. 1, pp. 45-45
Open Access | Times Cited: 17
Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B
Sayeh Ezzikouri, Mohammad Enamul Hoque Kayesh, Soumaya Benjelloun, et al.
Vaccines (2020) Vol. 8, Iss. 2, pp. 216-216
Open Access | Times Cited: 17
Is PD-1 blockade a potential therapy for HBV?
Cyrille Féray, F. Xavier López‐Labrador
JHEP Reports (2019) Vol. 1, Iss. 3, pp. 142-144
Open Access | Times Cited: 17
IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases
Xuefen Li, Xia Liu, Weilin Wang
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 13
Treatments for HBV: A Glimpse into the Future
Alessandra Bartoli, Filippo Gabrielli, Andrea Tassi, et al.
Viruses (2021) Vol. 13, Iss. 9, pp. 1767-1767
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top